These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38095885)

  • 1. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
    Ghoreifi A; Vaishampayan U; Yin M; Psutka SP; Djaladat H
    JAMA Oncol; 2024 Feb; 10(2):240-248. PubMed ID: 38095885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study.
    Yip W; Ghoreifi A; Gerald T; Lee R; Howard J; Asghar A; Khanna A; Cai J; Aron M; Gill I; Thompson RH; Uzzo R; Margulis V; Singla N; Djaladat H
    Eur Urol Oncol; 2023 Dec; 6(6):604-610. PubMed ID: 37005212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
    Vaishampayan UN
    Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis.
    Satkunasivam R; Guzman JC; Klaassen Z; Hall ME; Luckenbaugh AN; Lim K; Laviana AA; DeRosa AP; Beckermann KE; Rini B; Wallis CJ
    Urol Oncol; 2022 Feb; 40(2):64.e17-64.e24. PubMed ID: 34690032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
    Kuusk T; Abu-Ghanem Y; Mumtaz F; Powles T; Bex A
    Curr Opin Urol; 2021 May; 31(3):262-269. PubMed ID: 33742979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
    Carlo MI; Attalla K; Mazaheri Y; Gupta S; Yildirim O; Murray SJ; Coskey DT; Kotecha R; Lee CH; Feldman DR; Russo P; Patil S; Motzer RJ; Coleman JA; Durack JC; Chen YB; Akin O; Ari Hakimi A; Voss MH
    Eur Urol; 2022 Jun; 81(6):570-573. PubMed ID: 35183395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
    Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
    Gross EE; Li M; Yin M; Orcutt D; Hussey D; Trott E; Holt SK; Dwyer ER; Kramer J; Oliva K; Gore JL; Schade GR; Lin DW; Tykodi SS; Hall ET; Thompson JA; Parikh A; Yang Y; Collier KA; Miah A; Mori-Vogt S; Hinkley M; Mortazavi A; Monk P; Folefac E; Clinton SK; Psutka SP
    Urol Oncol; 2023 Jan; 41(1):51.e25-51.e31. PubMed ID: 36441070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative systemic therapy in renal cell carcinoma.
    MacPhail C; Wood LA; Thana M
    Curr Opin Support Palliat Care; 2023 Dec; 17(4):301-307. PubMed ID: 37800628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.
    Mori K; Quhal F; Yanagisawa T; Katayama S; Pradere B; Laukhtina E; Rajwa P; Mostafaei H; Sari Motlagh R; Kimura T; Egawa S; Bensalah K; Karakiewicz PI; Schmidinger M; Shariat SF
    Int Immunopharmacol; 2022 Jul; 108():108720. PubMed ID: 35339843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
    Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
    Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
    Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology.
    Tobert CM; Uzzo RG; Wood CG; Lane BR
    Urol Oncol; 2013 Oct; 31(7):1316-20. PubMed ID: 22264501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
    Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
    World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.